Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use

N/AWithdrawnNCT01219114

AstraZeneca200 enrolled

Overview

The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions of actual use in patients who are diagnosed with complicated Skin and Skin Structure infection (cSSI) or Staphylococcus aureus bacteria including right-sided endocarditis and are prescribed CUBICIN by their physician.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of cSSSI known or suspected to be due to gram-positive bacteria * Diagnosis of right-sided endocarditis with one or more positive culture for S. aureus within two days prior to initiation of medication * Prescribed daptomycin by patient's attending physician Exclusion Criteria: * Known allergic or serious adverse reaction to daptomycin * Patients with pneumonia * Patients with baseline CPK values \>1000 U/L or 5x ULN

Locations (5)

Research Site

Lipa City, Batangas, Philippines

Research Site

Davao City, Davao Region, Philippines

Research Site

Iloilo City, Iloilo, Philippines

Research Site

Pasig, National Capital Region, Philippines

Outcomes

Primary Outcomes

Adverse events observed during the treatment duration

Time frame: Ranges from during treatment and up to 14 days after last administration of daptomycin (follow up)

Clinical Response determined by cure rate

Time frame: Ranges from during treatment and up to 14 days after last administration of daptomycin

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.